SK Plasma

What SK Plasma does

SK Plasma is a South Korea-based plasma fractionation company spun off from SK Chemicals in 2015 and operating as a subsidiary of SK Discovery within the SK Group conglomerate. The company manufactures and distributes plasma-derived medicinal products (PDMP) — including Albumin (SK Albumin 5% and 20%), Immunoglobulin (Liv-Gamma SN), Coagulation Factor VIII products (Tetabulin SN Prefilled Syringe, IV Hepabulin SN, ETBI), and Antithrombin III — using proprietary fractionation, purification, and multi-stage virus inactivation/removal processes at its KGMP-approved Andong Plant. SK Plasma distributes its products to healthcare providers, hospitals, and government health authorities across 20+ countries.

The company's revenue model spans four streams: (1) finished product exports to healthcare institutions and government health authorities, (2) toll manufacturing where it processes locally collected plasma from partner countries and returns derivative products, (3) technology transfer and licensing arrangements with national governments seeking plasma self-sufficiency, often including equity participation in joint ventures, and (4) license-in/co-promotion deals broadening the portfolio into hematology, oncology, immunology, and surgery therapeutic areas. The technology transfer franchise is exemplified by the Proturk JV with Turkish Red Crescent in Turkey (€65M licensing deal, ~$580M plant investment) and PT SK Plasma Core Indonesia JV (backed by Indonesia Investment Authority and Danantara sovereign wealth funds, $150M facility).

SK Plasma's strategic positioning targets the WHO-essential medicines segment with a vertically integrated "collection-to-commercial" value proposition, claiming 8-10% pricing advantage versus imported alternatives. The company is publicly listed in South Korea, led by CEO Kim Seungjoo, with executive support from Executive Strategy Director Heo Ji-ho appointed in December 2024. Strategic assets include over 50 years of accumulated plasma fractionation expertise (originating from Dongshin Pharma, 1970), KGMP regulatory approvals, and a growing global footprint anchored by long-duration government contracts.

Name

SK Plasma

Legal name

에스케이플라즈마 주식회사 (SK Plasma Co., Ltd.)

Website

https://skplasma.com

Company type

Public

Founded year

1970

Operating status

Operating

Headcount range

101–250 employees

Short description

SK Plasma is a South Korean plasma fractionation company producing blood-derived medicines (Albumin, Immunoglobulin, Factor VIII, Antithrombin III) for healthcare providers and government health authorities in 20+ countries, with a growing technology transfer and joint venture franchise targeting national plasma self-sufficiency in Indonesia and Turkey.

Ownership category

akta.pro rank

Product category

Plasma-derived medicinal products / Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industries

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Albumin Therapies (HLAIAHAC), Plasma-Derived Therapy Fill-Finish & Packaging (HLAIAHAJ), Plasma-Derived Therapy Cold Chain & Specialty Logistics (HLAIAHAL)

Keywords

• Plasma fractionation
• Blood products manufacturing
• Plasma-derived therapeutics
• Biopharmaceutical manufacturing
• Immunoglobulin production

Headquarters

HQ city

Pangyo

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Infrastructure, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Finished Product Sales: Manufacturing and distributing plasma-derived products worldwide including Albumin, Immunoglobulin G, Factor VIII, and other blood products to global markets through strategic partnerships.
2. Toll Manufacturing: Receiving locally collected plasma from partner countries and returning derivative products after processing, maximizing project value during periods when local fractionation facilities are under development.
3. Technology Transfer and Licensing: Transferring manufacturing expertise and technology to enable national self-sufficiency in plasma-derived medicines, including licensing fees and equity participation in joint ventures.
4. License-in and Co-promotion: Expanding portfolio beyond plasma-derived products through in-licensing, co-marketing, and co-promotion arrangements in therapeutic areas including hematology, oncology, immunology, and surgery.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

SK Plasma manufactures and supplies plasma-derived medicinal products (PDMPs) including Albumin (SK Albumin 5% and 20%), Immunoglobulin G (Liv-Gamma SN 5%/10%), Coagulation Factor VIII (Tetabulin SN Prefilled Syringe, IV Hepabulin SN, ETBI), Antithrombin III (SK Antithrombin III 500 I.U.), and fibrin sealant (Beriplast-P) to hospitals and healthcare providers in 20+ countries. In parallel, the company operates a global services business — finished product exports, toll manufacturing of locally collected plasma, and full technology transfer/licensing of fractionation know-how to enable national self-sufficiency (exemplified by €65M Proturk JV in Turkey and $150M Indonesia JV).

Product overview

SK Plasma is a plasma-derived medicinal products company that produces and supplies blood products including Albumin (SK Albumin 5% and 20%), Immunoglobulin (Liv-Gamma SN products in 5% and 10% concentrations), Coagulation Factors (Tetabulin SN Prefilled Syringe, IV Hepabulin SN, ETBI), and Antithrombin III (SK Antithrombin III 500 I.U.). The company operates plasma fractionation facilities in Korea (Andong Plant with KGMP approval since 2018) and provides toll-manufacturing, technology transfer, and license-in services globally. The product portfolio is manufactured through fractionation, purification, and virus inactivation processes, with distribution to over 20 countries. SK Plasma also offers Appstira (앱스틸라) with device kit programs and sells Belcade (벨케이드) for blood cancer treatment.

Differentiator

Problem solved

Functional benefit

Brands

• Appstila (앱스틸라): A product brand mentioned on the product list page - appears to be a blood product or therapeutic medication
• Buliflast-P (베리플라스트-피)
• Proturk
• PT SK Plasma Core Indonesia

Products and services

• SK Albumin 20% Inj. 20% human albumin solution for treatment of shock from excessive bleeding, burns, liver/kidney disease, and low plasma protein levels. Manufactured under advanced fractionation and virus inactivation processes for hospitals and healthcare institutions.
• SK Albumin 5% Inj. 5% human albumin solution for treatment of shock from excessive bleeding, burns, liver/kidney disease, and low plasma protein level. Used by hospitals for volume restoration and hypoalbuminemia management.
• Liv-Gamma SN Inj. Immunoglobulin product (5% and 10% concentrations) for treatment of congenital or acquired immunoglobulin deficiency, severe infection, and autoimmune diseases. Used by hematology/immunology clinicians.
• Tetabulin SN Inj. Prefilled Syringe Coagulation Factor VIII product in prefilled syringe form for hemophilia A treatment. Provides improved patient convenience with easier administration and improved storage conditions versus traditional lyophilized forms.
• IV Hepabulin SN Inj. Intravenous coagulation Factor VIII product for treatment and prevention of bleeding episodes in hemophilia A patients.
• SK Antithrombin III Inj. 500 I.U. Antithrombin III replacement therapy for treatment and prevention of thrombosis in patients with congenital or acquired antithrombin III deficiency.
• ETBI Inj. 250 IU Coagulation factor product for treatment of bleeding episodes associated with coagulation factor deficiencies.
• Beriplex-P (벨리플라스트-피) Combination Set 1 mL, 3 mL Fibrin sealant product in combination sets (1 mL, 3 mL) for hemostasis application during surgical procedures.
• Appstira (앱스틸라) Blood Product with Device Kit Program Plasma-derived therapeutic available with Start Pack (시작팩) and Maintenance Pack (유지팩) device kit options for patient administration.
• Belcade (벨케이드) Exclusive Sales Partnership Exclusive sales partnership for a blood cancer treatment product, expanding SK Plasma's portfolio in the oncology therapeutic area through an in-licensing/co-promotion arrangement.
• Plasma Fractionation Services (Toll Manufacturing) Toll-manufacturing services for countries and regions that collect plasma locally but lack fractionation capacity. SK Plasma processes locally collected plasma and returns derivative products, maximizing project value during build-out of local fractionation facilities.
• Technology Transfer Solutions Complete technology transfer services supporting national self-sufficiency by transferring expertise in plasma-derived medicine manufacturing, including R&D, production technologies, facility setup consultation, and operational training (exemplified by the €65M Proturk deal and PT SK Plasma Core Indonesia JV).
• Finished Product Export Export of plasma-derived finished products including Albumin, Immunoglobulin G, and Factor VIII to international markets meeting cGMP standards. Supplies 20+ countries worldwide.
• License-in and Co-promotion Services Business development services for co-marketing, co-promotion, and in-licensing of products in therapeutic areas including hematology, oncology, immunology, and surgery (e.g., Aimed Bio AMB303 pipeline, Janssen Korea Dacogen Inj.).

Quantifiable outcome

• Indonesia to achieve self-sufficiency in plasma-derived medicinal products
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Turkish Red CrescentcoreStrategic or Co-development Partner · 15 June 2026Joint venture Proturk for plasma fractionation plant in Cubuk, Ankara. Groundbreaking ceremony held June 2026. Facility will process 600,000 liters annually producing albumin, immunoglobulin, and Factor VIII. Investment of approximately €500 million ($580 million) with commercial production expected 2030.
• Proturk (Turkish Red Crescent Joint Venture)coreStrategic or Co-development Partner · 5 March 2026€65 million technology transfer and licensing agreement - SK Plasma's largest technology export deal. SK Plasma grants license to manufacture plasma-derived pharmaceuticals, transfers R&D and production technologies, and acquired 15% stake for €150,000. Facility will produce albumin, immune globulin locally in Turkey.
• PT SK Plasma Core IndonesiacoreStrategic or Co-development Partner · 19 January 2025Joint venture entity established for Indonesia's first plasma fractionation plant. 98.72% construction complete as of January 2026. Represents technology transfer initiative with Indonesian employees trained at SK Plasma's Korea facility.
• Janssen Korea (Johnson & Johnson)minorChannel Partner/ Reseller/ Distributor · 13 February 2023Sales and distribution agreement for Dacogen Inj. (anticancer drug), expanding SK Plasma's presence in oncology therapeutic area through partnership with global pharmaceutical company.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Takeda Pharmaceutical: Global pharmaceutical major whose plasma-derived therapy franchise (inherited from Shire/Baxalta) competes with SK Plasma in albumin and immunoglobulin markets. Much larger and more diversified; competes on breadth rather than plasma specialization.
• Sanofi: Global pharmaceutical major with a specialty care plasma franchise offering overlapping therapies (e.g., Cablivi for rare blood disorders). Operates broadly in immunology and rare disease rather than as a pure-play plasma competitor.

Direct peers

• CSL Behring: The world's largest plasma fractionator and the global benchmark for plasma-derived therapies including albumin, immunoglobulins, and coagulation factors. Directly competes with SK Plasma across the same core therapeutic categories and customer segments (hospitals, governments).
• Kedrion: Italian plasma-derived therapy manufacturer serving global markets with a portfolio similar to SK Plasma's (albumin, IVIG, coagulation factors). A closely comparable mid-sized private peer with international expansion ambitions.
• Grifols: Spanish global leader in plasma-derived medicines with vertically integrated plasma collection and fractionation. Competes head-to-head with SK Plasma in albumin, IVIG, and Factor VIII, and is a likely incumbent that SK Plasma displaces in emerging-market tenders.
• Octapharma: Privately held Swiss plasma fractionator with a portfolio overlapping SK Plasma's core products (albumin, immunoglobulins, coagulation factors). Operates a similar global multi-market model, including technology licensing to partner countries.
• Biotest: German plasma fractionator producing albumin, immunoglobulins, and coagulation factors. Now controlled by Creat Group, with a comparable product mix and international footprint to SK Plasma.

Emerging players

• ADMA Biologics: US-based plasma-derived therapeutics company focused on immune globulins for immunodeficient patients. A smaller, emerging competitor in the specialty plasma niche that overlaps with SK Plasma's Liv-Gamma franchise.

Regional players

• Shanghai RAAS Blood Products: One of China's largest blood product manufacturers with a portfolio of plasma-derived therapies including albumin and immunoglobulins. A comparable regional player focused primarily on the Chinese market.
• GC Biopharma (formerly Green Cross): South Korean biopharmaceutical company with a plasma-derived product portfolio (albumin, immunoglobulins) and blood product distribution. The closest direct domestic competitor to SK Plasma in Korea and select Asian markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SK Plasma